Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03663257 · ClinicalTrials.gov registry record
Study to Evaluate Cerebral AneurysmFlow Results in Occlusion
A clinical trial, sponsored by Philips Clinical & Medical Affairs Global.
- Completed
- Registry status
- 132
- Enrollment target
NCT03663257 is a clinical trial that has completed, run by Philips Clinical & Medical Affairs Global. The registered enrollment target is 132 participants.
The verdict
NCT03663257 has completed, sponsored by Philips Clinical & Medical Affairs Global.
- COMPLETED
- Registry status
- 132 participants
- Enrollment target
Study Summary
AneurysmFlow R1.0 is an approved (i.e. CE labeled, 510k, Health Canada), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric flow rate quotient before and after Flow Diverter Stent (FDS) implantation in the region of interest. The current study is a prospective, single arm, observational, multicenter cohort study to assess the prognostic value of the MAFA ratio for predicting full aneurysm occlusion 12 months after flow diverter placement.
Interventions
- DEVICE AneurysmFlow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2023-11-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03663257
The ClinicalTrials.gov registry entry for NCT03663257 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Philips Clinical & Medical Affairs Global, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AneurysmFlow is the first listed.
NCT03663257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03663257 about?
NCT03663257 is a clinical study titled "Study to Evaluate Cerebral AneurysmFlow Results in Occlusion". AneurysmFlow R1.0 is an approved (i.e. CE labeled, 510k, Health Canada), software tool intended to provide relevant information on the blood flow in a cerebral aneurysm and its parent artery based on angiography. It calculates the Mean Aneurysm Flow Amplitude (MAFA) ratio to measure the volumetric f...
What is the current status of trial NCT03663257?
This trial is currently completed. The enrollment target is 132 participants. The study started on 2018-10-04. Estimated completion is 2023-11-27.
What interventions are being tested in trial NCT03663257?
The interventions under investigation include: AneurysmFlow (DEVICE).
Who is sponsoring clinical trial NCT03663257?
This trial is sponsored by Philips Clinical & Medical Affairs Global, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.